複製鏈接
請複製以下鏈接發送給好友
https://baike.baidu.hk/item/胡文輝/10872775
複製
複製成功

胡文輝

（廣州醫科大學藥學院特聘教授）

鎖定
胡文輝，男，博士，現任廣州醫科大學藥學院特聘教授，藥物化學專業博士生導師，兼學術委員會主任，廣東省分子靶標與臨牀藥理重點實驗室副主任，呼吸病國家重點實驗室研究員 [1]  。
胡博士於2002年畢業於中國協和醫科大學藥物研究所，師從郭宗儒教授，開展抗炎藥物的研究，獲得博士學位。2002年-2006年在美國西北大學醫學院從事博士後研究,開展神經退行性疾病的藥物研究。2006年-2016年在中國科學院廣州生物醫藥與健康研究院歷任副研究員、研究員、新藥開發室主任。
在歷時20多年的新藥研究中，胡教授團隊已確立多個全新結構的候選藥物。其中，基於神經膠質細胞功能障礙的抗阿爾茨海默氏症新藥AD16（GIBH130、哌噠甲酮片），已獲得國家食品藥品監督管理局（CFDA）頒發的1.1類藥物臨牀試驗批件（ 批件號：2016L02442，2016L02443，2016L02444），化合物專利涵蓋了全球多個國家。相關的研究以通訊作者的論文發表在Angewandte Chemie International Edition，Journal of Medicinal Chemistry、Organic Letters、European Journal of Medicinal Chemistry等學術刊物，並在Advanced Synthesis &Catalysis, ChemCatChem和科學通報上發表了封面文章。
中文名
胡文輝
性 別
男
職 稱
研究員
學 歷
博士
畢業院校
中國協和醫科大學

目錄

  1. 1 人物簡介
  2. 2 研究方向
  3. 3 科研項目
  1. 4 所獲榮譽
  2. 5 主要成就
  3. ▪ 項目成果
  1. ▪ 代表論文

胡文輝人物簡介

胡文輝，男，博士生導師，廣東省“珠江學者”特聘教授，藥物化學學科帶頭人，廣州市蛇毒與生物毒素研究所所長，兼廣州醫科大學藥學院學術委員會主任，廣東省分子靶標與臨牀藥理重點實驗室副主任，呼吸病國家重點實驗室研究員。
胡教授於2002年畢業於中國協和醫科大學藥物研究所，師從郭宗儒教授，開展抗炎藥物的研究，獲得博士學位。2002年-2006年在美國西北大學醫學院從事博士後研究，開展神經退行性疾病的藥物研究。2006年-2016年在中國科學院廣州生物醫藥與健康研究院歷任副研究員、研究員、新藥開發室主任。
立足於尚無有效藥物的重大疾病，胡文輝課題開展創新藥物的研究，建立了國內具有特色和優勢的新藥研發團隊。在歷時20多年的新藥研究中,胡教授團隊已確立多個全新結構的候選藥物。其中，基於神經膠質細胞功能障礙的抗阿爾茨海默氏症新藥AD16（哌達甲酮），已獲得國家食品藥品監督管理局（CFDA）頒發的1.1類藥物臨牀試驗批件，正在開展臨牀試驗中，化合物專利涵蓋了全球多個國家。截至目前，已發表了30多篇國際學術論文，申請了30多項國家、國際發明專利，兼任藥學學報的編委、廣東省藥學會藥物化學專業委員會副主委。 [3] 
2008年，胡文輝帶領團隊設計、發明了抗阿爾茨海默氏症新藥AD16（哌噠甲酮片），2021年11月4日，（哌噠甲酮片）已完成了一期臨牀，呈現出良好的安全性和耐受性。 [2] 

胡文輝研究方向

創新藥物研究 [3] 

胡文輝科研項目

已主持國家科技部、國家自然科學基金委、廣東省科技廳的新藥重大專項，企業橫向經費等各類新藥基金近20項，金額逾2000多萬元。目前的在研課題：國家自然科學基金面上項目，81872743，神經膠質細胞調節劑AD110延緩阿爾茨海默氏症的作用及機制研究。 [3] 

胡文輝所獲榮譽

2011年獲得廣東省優秀共產黨員，2014年獲得廣東省優秀專利獎， 2018年獲“珠江學者”特聘教授，2020年獲廣東省科技進步一等獎（第二負責人）。 [3] 

胡文輝主要成就

胡文輝項目成果

立足於尚無有效藥物的重大疾病，開展化學生物學和創新藥物的研究，解決關鍵的科學問題或研發具有開發前景的新藥，建立國內具有特色和優勢的新藥研發團隊。胡教授已申請了30多項國際和國家發明專利，主持國家科技部、廣東省科技廳的新藥重大專項，企業橫向經費等各類新藥基金2000多萬元，發表了30多篇國際學術論文，兼任藥學學報的青年編委。

胡文輝代表論文

  1. Ping Sun, Hu Yue, Qi Xing, Wenming Deng, Yitao Ou, Guangjin Pan, Xiaofen Zhong*, Wenhui Hu*. Compound AD16 reduces amyloid plaque deposition and modifies microglia in a transgenic mouse model of Alzheimer's disease. ACS Pharmacology & Translational Science. 2020. (In Press). [3] 
  2. Jianghong Dong, Mengjie Xiao, Qinge Ma, Guicheng Zhang, Weijie Zhao, Mengjie Kong, Yue Zhang, Luyun Qia, Wenhui Hu*. Design and synthesis of pinane oxime derivatives as novel anti-influenza agents. Bioorganic Chemistry. 2020, 102, 104106-104106. [3] 
  3. Nannan Wu, Guangyu Lian, Jingyi Sheng, Dan Wu, Huiyao Lan, Wenhui Hu*, Zhongjin Yang*. Discovery of a Novel Selective Water-Soluble SMAD3 Inhibitor as an Antitumor Agent. Bioorganic Medicinal Chemistry letter. 2020, 30 (17), 127396. [3] 
  4. Yitao Ou, Ping Sun, NanNan Wu, Hao Chen, Wenhui Hu*, Zhongjin Yang*. Synthesis and biological evaluation of parthenolide derivatives as potential inhibitors of the NLRP3 inflammasome. Bioorganic Medinal Chemistry letter. 2020, 30 (17), 127399. [3] 
  5. Ping Sun, Wei Zhou, Hu Yue, Cheng Zhang, Yitao Ou, Zhongjin Yang*, Wenhui Hu*. Compound AD110 Acts as Therapeutic Management for Alzheimer’s Disease and Stroke in Mouse and Rat Models. ACS Chemical Neuroscience, 2020, 11 (6), 929-938. [3] 
  6. Wenmin Deng , Zhongjin Yang, Hu Yue, Yitao Ou, Wenhui Hu*, Ping Sun*. Disulfiram suppresses NLRP3 inflammasome activation to treat peritoneal and gouty inflammation. Free Radical Biology and Medicine, 2020, 152, 8-17. [3] 
  7. Xin Zhao, Runfeng Li, Yang Zhou, Mengjie Xiao, Chunlong Ma, Zhongjin Yang, Shaogao Zeng, Qiuling Du, Chunguang Yang, Haiming Jiang, Yanmei Hu, Ping Sun, Jianghong Dong, Wei Cui, Kefeng Wang, Jun Wang, Yaoquan Tu, Zifeng Yang, Wenhui Hu*. Discovery of Highly Potent Pinanamine-Based Inhibitors Against Amantadine- and Oseltamivir-resistant Influenza A Viruses. Journal of Medicinal Chemistry. 2018, 61, 5187−5198. [3] 
  8. Zhengtu Li, Junling Zhao, Hongxia Zhou, Li Li, Yuyang Ding, Jing Li, Beixian Zhou,Haiming Jiang, Nanshan Zhonga, Wenhui Hu*, Zifeng Yang*. Cappariloside A shows antiviral and better anti-inflammatory effects against influenza virus via regulating host IFN signaling, in vitro and vivo. Life Sciences 200 (2018) 115–125. [3] 
  9. Hui Xie, Shaogao Zeng, Yuwen He, Guicheng Zhang, Pengjiu Yu, Guifa Zhong, Hongjiang Xu, Ling Yang, Shanchun Wang, Xin Zhao*, Wenhui Hu*. Rapid generation of a novel DPP-4 inhibitor with long-acting properties: SAR study and PK/PD evaluation. European Journal of Medicinal Chemistry, 2017, 141, 519-529. (IF=4.5)
  10. Yunlong Zhao, Qingxin Zhao, LS Wang, Wen Hui Hu*, Jun Ling Zhao*. Organocatalytic Friedel-Crafts Alkylation /Lactonization Reaction of Naphthols with 3-Trifluoroethylidene Oxindoles: The Asymmetric Synthesis of Dihydrocoumarins. AngewandteChemie International Edition. 2017, 56, 338 –342. (IF =12.0)
  11. Wei Zhou, Guifa Zhong, Sihai Fu, Hui Xie, Tianyan Chi, Luyi Li, Xiurong Rao，Shaogao Zeng, Dengfeng Xu, Hao Wang, Guoqing Sheng, Xing Ji, Xiaorong Liu, Xuefei Ji, Donghai Wu, Libo Zou, Micky Tortorella, Kejian Zhang, and Wenhui Hu*. Microglia-based phenotypic screening identifies a novel inhibitor of neuroinflammation effective in Alzheimer's Disease Models. ACS Chemical Neuroscience. 2016, Nov 16;7 (11):1499-1507. (IF =3.9)
  12. Jianghong Dong, Shengwei Chen, Runfeng Li, Wei Cui, Haiming Jiang, Yixia Ling, Zifeng Yang, Wenhui Hu*. Imidazole-based pinanamine derivatives: Discovery of dual inhibitors of the wild-type and drug-resistant mutant of the influenza A virus. European Journal of Medicinal Chemistry. 2016, 108,605-615. (IF=4.5)
  13. Shengwei Chen, Qinxin Lou, Yuyang Ding, Shasha Zhang, Wenhui Hu* and Junling Zhao* Organocatalytic enantioselective Michael reaction of malononitrile to b,b-disubstituted nitroalkenes. Advanced Synthesis & Catalysis. 2015, 357, 2437-2441. (Front Cover and Very Important Publication). (IF =5.6)
  14. Shengwei Chen, Guicheng Zhang, Qxinxin Lou, Wei Cui, Shasha Zhang, Wenhui Hu* and Junling Zhao*. Organocatalytic enantioselective aza-Michael reaction of benzotriazole to β,β-disubstituted nitroalkenes. ChemCatChem. 2015, 7, 1935-1938. (Inside Back Cover). (IF =4.8)
  15. Yuyang Ding, Liufeng Mao, Dengfeng Xu, Hui Xie, Ling Yang, Hongjiang Xu, Wenjun Geng, Yong Gao, Chunguang Xia, Xiquan Zhang, Qingyi Meng, Donghai Wu, Junling Zhao * and Wenhui Hu*. C-aryl glucoside SGLT2 inhibitors containing a biphenyl motif as potential anti-diabetic agents. Bioorganic Medinal Chemistry letter. 2015, 25, 2744-2748. (IF =2.8)
  16. Bo Bi, Qin-Xin Lou, Yu-Yang Ding, Sheng-Wei Chen, Sha-Sha Zhang, Wen-Hui Hu* and Jun-Ling Zhao* Chiral phosphoric acid-catalyzed highly enantioselective Friedel-Crafts alkylation reaction of C3-substituted indoles to unsaturated ketimino esters.Organic Letters, 2015, 17, 540−543.(IF =6.6)
  17. Wei Cui, Shengwei Chen, JiaQiang Wu, Xin Zhao*,Wenhui Hu*, and Honggen Wang*, Palladium-Catalyzed Remote C(sp3)−H Arylation of 3‑Pinanamine. Organic Letters.2014, 16, 4288−4291.(IF =6.6)
  18. 周渭, 胡文輝. 神經炎症抑制劑用於阿爾茨海默症的藥物研發. 科學通報. 2014. 59(3): 232 - 237. （封面文章）
  19. Wei Zhou, Wenhui Hu*. Anti-neuroinflammatory agents for the treament of Alzheimer’s disease. Future Medicinal Chemistry. 2013.5 (13): 1-13. (IF =3.6)
  20. Hui Xie, Lili Zeng, Shaogao Zeng, Xin Lu, Xin Zhao, Guicheng Zhang, Zhengchao Tu, Hongjiang Xu, Ling Yang, Xiquan Zhang, Shanchun Wang*, Wenhui Hu*. Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization. European Journal of Medicinal Chemistry. 2013, 68, 312-320. (IF=4.5)
  21. Shaogao Zeng, Hui Xie, L-li Zeng, Xin Lu, Xin Zhao, Gui-cheng Zhang, Zhengchao Tu, Hongjiang Xu, Ling Yang, Xiquan Zhang, Wenhui Hu*. Discovery of potent dipeptidyl peptidase IV inhibitors through pharmacophore hybridization and hit-to-lead optimization. Bioorganic & Medicinal Chemistry. 2013. 21(7):1749-55. (IF=2.9)
  22. Xin Zhao, Yanling Jie, Matthew R. Rosenberg, Junting Wan, Shaogao Zeng, Wei Cui, Yiping Xiao, Zhiyuan Li, Zhengchao Tu, Marco G. Casarotto, Wenhui Hu*. Design and Synthesis of Pinanamine Derivatives as Anti-Influenza A M2 Ion Channel Inhibitors. Antiviral Research. 2012, 96(2):91-99. (IF=4.3)
  23. Wei Zhou, Guifa Zhong, Xiurong Rao, Hui Xie, Shaogao Zeng, Tianyan Chi, Libo Zou, Donghai Wu, Wenhui Hu*. Identification of aminopyridazine-derived anti-neuroinflammatory agents effective in an alzheimer’s mouse model. ACS Medicinal Chemistry Letters. 2012, 3 (11): 903–907. (IF=3.7)
  24. Hui Xie, Lili Zeng, Shaogao Zeng, Xin Lu, Guicheng Zhang, Xin Zhao, Na Cheng, Zhengchao Tu, Zhiyuan Li, Hongjiang Xu, Ling Yang, Xiquan Zhang, Min Huang, and Wenhui Hu*. Novel pyrrolopyrimidine analogues as potent dipeptidyl peptidase IV inhibitors based on pharmacokinetic property-driven optimization. European Journal of Medicinal Chemistry. 2012, 52:205-12. (IF=4.5)
  25. Hong Li, Junling Zhao, Lili Zeng, Wenhui Hu*. Organocatalytic asymmetric domino aza-Michael-Mannich reaction: synthesis of tetrahydroimidazopyrimidine derivatives. Journal of Organic Chemistry. 2011, 76(19): 8064-9. (IF=4.8)
  26. Xin Zhao, Chufang Li, Shaogao Zeng, Wenhui Hu*. Discovery of highly potent agents against influenza A virus. European Journal of Medicinal Chemistry. 2011, 46 (1):52-57. (IF=4.5)
  27. Jifeng Deng, Li Peng, Guicheng Zhang, Xiaobing Lan, Chufang Li, Fuxin Chen, Yayao Zhou, Zuoxian Lin, Ling Chen, Renke Dai, Hongjiang Xu, Ling Yang, Xiquan Zhang, Wenhui Hu*. The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes. European Journal of Medicinal Chemistry.2011, 46 (1): 71-76. (IF=4.5)
  28. Wenhui Hu*, Shaogao Zeng, Chufang Li，Yanling Jie, Zhiyuan Li and Ling Chen. Identification of Hits as Matrix-2 Inhibitors through the Focused Screening of a Small Primary Amine Library.Journal of Medicinal Chemistry. 2010, 53(9): 3831-3834. (IF=6.3)
參考資料